Global Peripheral Circulatory Disease Treatment Market, By Type (Peripheral Vascular Diseases and Peripheral Artery Diseases), Treatment (Cholesterol Lowering Medications, High Blood Pressure Medication, Medication to Prevent Blood Clots), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Peripheral Circulatory Disease Treatment Market Analysis and Size
The growing incidence of diabetes disorder and the rising aging population support the growth of the peripheral circulatory disease treatment market. In addition to this, the rising blood flow increases with increased high exercise intensity in skeletal, respiratory and cardiac muscles, which may expect to boost the growth for the peripheral circulatory disease treatment market. However, the availability of alternative treatments, product recalls, and product failures are the factors limiting the growth of the peripheral circulatory disease treatment market.
Data Bridge Market Research analyses a growth rate in the peripheral circulatory disease treatment market in the forecast period 2023-2030. The expected CAGR of peripheral circulatory disease treatment market is tend to be around 7.50% in the mentioned forecast period. The market was valued at USD 4.5 billion in 2022, and it would grow upto USD 8.03 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Peripheral Circulatory Disease Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Peripheral Vascular Diseases and Peripheral Artery Diseases), Treatment (Cholesterol Lowering Medications, High Blood Pressure Medication, Medication to Prevent Blood Clots), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Abbott (U.S.)., Edwards Lifesciences Corporation (U.S.), Medtronic (Ireland), Teleflex Medical Private Limited (India), Boston Scientific Corporation (U.S.), Cook (U.S.), Cordis (U.K.), Terumo Interventional Systems (U.S.)., Bayer AG (Germany), Endologix (U.S.), B Braun SE (Germany)
|
|
Market Opportunities
|
|
Market Definition
Peripheral circulation disease is associated with the transport of blood, blood flow distribution, exchange between blood and tissue and storage of blood. The system consists of systemic circulation, which supplies blood to all body parts except the lungs, and the pulmonary circulation, which supplies blood to lungs whose role is to alter the distribution of blood to meet the needs of the various tissues. Peripheral circulatory disease is a type of condition in which narrowed blood vessels reduce blood flow to limbs.
Peripheral Circulatory Disease Treatment Market Dynamics
Drivers
- Increasing demand of minimally invasive surgery
Minimally invasive endovascular procedures expand the artery opening, such as angioplasty or atherectomy, and are currently employed more frequently than bypass surgery as the initial treatment strategy for peripheral circulatory disease. The two main forms of endovascular therapies for the diseased condition are balloon angioplasty with stenting and atherectomy. Endovascular therapy or vascular surgery can be used to treat patients with severe peripheral circulatory disease.
- Growing strategic associations
Several companies have adopted a number of developmental strategies in the past few years. For instance, in September 2020, Abbott Laboratories started the LIFE-BTK clinical trial to evaluate the effectiveness and safety of its Esprit BTK Everolimus Eluting Resorbable Scaffold System. The Investigational Device Exemption (IDE) trial in the U.S. is projected to help people fighting the advanced stages of peripheral artery disease (PAD).
Opportunities
- Development of advanced technology
Several technological advancements are helping in expansing the growth of the market. Endovascular therapy outcomes have considerably improved as technology has advanced. Numerous innovative technologies are now being developed, such as paclitaxel-eluting stents, intravascular lithotripsy, percutaneous femoro-popliteal bypass, and the adventitial delivery of anti-restenosis medicines. Thus this factor helps in the advancement of the market.
- Introduction of novel products
The market for peripheral circulatory devices is expected to grow due to the introduction of novel products, such as upgraded drug-eluting vascular stents. For instance, the FDA granted Boston Scientific an investigational device exemption (IDE) in 2015 to initiate a global, pivotal study of the Eluvia drug-eluting stent. EluviaTM Drug-Eluting Vascular Stent System was designed particularly for treating peripheral artery disease, and in 2018, the U.S. FDA authorized its Premarket Approval (PMA) application.
Restraints/Challenges
- Device Limitations of various treatment procedures
Various device limitations during the surgical procedure pose a restrictive impact upon the market expansion. Numerous procedures involving drug-eluting balloons come with the risk of occurrence of restenosis after treatment.
- High cost
Often, due to lack of inappropriate payment plans and special considerations by the organizations, the patients fail to adapt various high-end treatment options, which hampers their health. The material cost composition of peripheral vascular devices is greater within institutional settings, and the high-cost burden of adoption of these devices is a factor, that hinders the overall market.
This peripheral circulatory disease treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the peripheral circulatory disease treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development:
- Cook Medical obtained FDA Breakthrough Device designation for a novel drug-eluting stent below the knee in January 2022. (BTK). This novel stent is intended to treat individuals with chronic limb-threatening ischemia (CLTI).
Global Peripheral Circulatory Disease Treatment Market Scope
The peripheral circulatory disease treatment market is segmented on the basis of type, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Peripheral Vascular Diseases
- Peripheral Artery Diseases
Treatment
- Cholesterol Lowering Medications
- High Blood Pressure Medication
- Medication to Prevent Blood Clots
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Peripheral Circulatory Disease Treatment Market Regional Analysis/Insights
The peripheral circulatory disease treatment market is analyzed and market size insights and trends are provided by type, treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the peripheral circulatory disease treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the high equipped infrastructure facilities, financed hospitals and clinics, high adoption rate of peripheral diseases
Asia-Pacific dominates the market due to increased prevalence of geriatric population and rapidly developing economic conditions.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Peripheral Circulatory Disease Treatment Market Share Analysis
The peripheral circulatory disease treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to peripheral circulatory disease treatment market.
Key players operating in the peripheral circulatory disease treatment market include:
- Abbott (U.S.)
- Edwards Lifesciences Corporation (U.S.)
- Medtronic (Ireland)
- Teleflex Medical Private Limited (India)
- Boston Scientific Corporation (U.S.)
- Cook (U.S.)
- Cordis (U.K.)
- Terumo Interventional Systems (U.S.)
- Bayer AG (Germany)
- Endologix (U.S.)
- B Braun SE (Germany)
SKU-